In the phase 3 CORALreef Lipids trial, the oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by 57% at 24 weeks and also lowered non-HDL cholesterol, apolipoprotein B, and lipoprotein(a). Adverse events were similar in the two groups. Full trial results:
nej.md/4qhQPtQ
Editorial: Exploring a New “Reef” in Dyslipidemic Risk Reduction
nej.md/4c67HjO